KK2223
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
T-cell NHL (PTCL or CTCL)
Conditions
T-cell NHL (PTCL or CTCL)
Trial Timeline
Jan 23, 2026 → Sep 1, 2030
NCT ID
NCT07192471About KK2223
KK2223 is a phase 1 stage product being developed by Kyowa Kirin for T-cell NHL (PTCL or CTCL). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07192471. Target conditions include T-cell NHL (PTCL or CTCL).
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07192471 | Phase 1 | Recruiting |
Competing Products
20 competing products in T-cell NHL (PTCL or CTCL)